Abstract
Neuroblastoma is the most common infant cancer, and new therapies are required for aggressive subtypes. Existing neuroblastoma therapeutics cause therapy-related toxicity, impairing patients? quality of life. NONO RNA-binding protein
was found to have an oncogenic role, whereas its long noncoding RNA binding target NEAT1 was found to have a tumour-suppressor role in high-risk neuroblastoma. NEAT1-promoting antisense oligonucleotide therapeutics were developed to inhibit neuroblastoma cell growth. NONO reduction experiments showed that NONO promotes cancer cell metabolism. Investigation of the NONO and NEAT1 molecules in neuroblastoma has led to the generation of RNA therapeutics that hold the potential to treat neuroblastoma patients.
was found to have an oncogenic role, whereas its long noncoding RNA binding target NEAT1 was found to have a tumour-suppressor role in high-risk neuroblastoma. NEAT1-promoting antisense oligonucleotide therapeutics were developed to inhibit neuroblastoma cell growth. NONO reduction experiments showed that NONO promotes cancer cell metabolism. Investigation of the NONO and NEAT1 molecules in neuroblastoma has led to the generation of RNA therapeutics that hold the potential to treat neuroblastoma patients.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 6 Aug 2020 |
| DOIs | |
| Publication status | Unpublished - 2020 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - NAVEED Alina - 2020 - Part 2
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.